Premium
A bispecific antibody detects cytotoxic T lymphocytes of unknown antigen specificity in patients with granular lymphocyte‐proliferative disorders
Author(s) -
Kaneko Takako,
Oshimi Kazuo,
Seto Takashi,
Okumura Ko,
Mizoguchi Hideaki
Publication year - 1992
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1992.tb08892.x
Subject(s) - ctl* , cytotoxic t cell , monoclonal antibody , cd3 , antigen , antibody , peripheral blood mononuclear cell , immunology , cd8 , cytotoxicity , in vivo , lymphocyte , t lymphocyte , microbiology and biotechnology , biology , in vitro , biochemistry
Summary. A simple and sensitive method for the detection of cytotoxic T lymphocytes (CTL) of unknown antigen specificity was investigated. Using anti‐CD3 Fab' × anti‐CD10 Fab' bispecific antibody or intact anti‐CD3 monoclonal antibody, we induced cytotoxicity for CD10 + , Fcγ receptor‐positive Daudi target cells in peripheral blood mononuclear cells (PBMC) obtained from patients with granular lymphocyte‐proliferative disorders (GLPD). The results indicated that the bispecific antibody was much more efficient than the intact anti‐CD3 monoclonal antibody in inducing cytotoxicity. Since CD3 + CD4 − CD8 + granular lymphocytes in patients with GLPD are considered to be in vivo ‐primed CTL of unknown antigen specificity, this bispecific antibody method may be useful for detecting in vivo ‐primed CTL within PBMC. By using this bispecific antibody, it will be possible to detect circulating in vivo ‐primed CTL in other clinical conditions.